This publication has been discontinued on May 30, 2012.
This IDC Health Insights Perspective discusses the importance of item-level serialization and its adoption within the pharmaceutical industry. Using a leading pharmaceutical company case study as a backdrop, this document examines the nuances, challenges, and best practices that pharmas will endure with serialization initiatives. This document also reviews potential benefits, causes of delay, and guidance on how manufacturers should approach business case construction to circumvent funding delays. Information in this document is based on a phone interview IDC Health Insights conducted with the pharmaceutical manufacturer discussed herein and is further supplemented by survey data collected in Life Science Leading Indicators 1Q12 (IDC Health Insights #HI232991, February 2012).